Comment: AVP-21D9 is a fully human IgG1 monoclonal antibody that targets the protective antigen (PA) component of Bacillus anthracis toxin [1-2]. It is being developed as an intravenous treatment for anthrax following exposure to B. anthracis.
The therapeutic efficacy of AVP-21D9 has been evaluated in animal models of inhalational anthrax, with survival of up to 92% of rabbits and 67% of cynomolgus macaques infected with B. anthracis [1].
